Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Merger or Acquisition (November 2025)

11 slides from Day One Biopharmaceuticals's merger presentation, Nov 13, 2025

  1. Slide 1: Acquisition of Mersana Therapeutics

    Slide 1: Acquisition of Mersana Therapeutics

    NOVEMBER 2025 Acquisition of Mersana Therapeutics

  2. Slide 2: Day One's Mission

    Slide 2: Day One's Mission

    2 Confidential Information. For internal use only. Day One’s Mission Inspired by the urgent needs of children, Day One creatively and intentionally develops new medicines for people of all ages with life - threatening diseases

  3. Slide 3: Forward Looking Statements

    Slide 3: Forward Looking Statements

    Forward Looking Statements 3 This communication contains forward - looking statements. Forward - looking statements are generally identified by the words “expect s”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, “will”, “goal” and similar expressions. These forward - looking statem ent

  4. Slide 4: Agenda & Day One Participants

    Slide 4: Agenda & Day One Participants

    4 Agenda & Day One Participants Overview & Opportunity Jeremy Bender (Chief Executive Officer) Transaction Rationale Michael Vasconcelles (Head of R&D) Financial Overview & Transaction Details Charles York (Chief Operating & Chief Financial Officer) Q&A Session All Participants

  5. Slide 5: Overview and Opportunity

    Slide 5: Overview and Opportunity

    Overview and Opportunity 5 Jeremy Bender Chief Executive Officer

  6. Slide 6: A Compelling Opportunity Aligned With Our Mission

    Slide 6: A Compelling Opportunity Aligned With Our Mission

    A Compelling Opportunity Aligned With Our Mission 6 ACC, Adenoid Cystic Carcinoma. Emi - Le, Emiltatug Ledadotin The Emi - Le program strengthens our mission, providing a novel opportunity for an innovative therapy with transformative impact Day One's existing research and development expertise, and

  7. Slide 7: Transaction Rationale

    Slide 7: Transaction Rationale

    Transaction Rationale 7 Michael Vasconcelles Head of R&D

  8. Slide 8: Emi-Le Represents A Transformational Opportunity To Address The Unmet Need For Patients With ACC

    Slide 8: Emi-Le Represents A Transformational Opportunity To Address The Unmet Need For Patients With ACC

    8 Emi - Le Represents A Transformational Opportunity To Address The Unmet Need For Patients With Adenoid Cystic Carcinoma (ACC) • ACC is a rare cancer, with an annual US incidence of ~1,300 patients 2 • Recurrent/metastatic ACC often presents with aggressive features; no approved therapeutic options

  9. Slide 9: Financial Overview & Transaction Details

    Slide 9: Financial Overview & Transaction Details

    Financial Overview & Transaction Details 9 Charles York Chief Operating Officer & Chief Financial Officer

  10. Slide 10: Financial Overview And Transaction Details

    Slide 10: Financial Overview And Transaction Details

    Financial Overview And Transaction Details 10 Major EMA market includes France, Germany, Italy, Spain or the United Kingdom. Emi - Le, Emiltatug Ledadotin Purchase Price $25 per share Approximately $129 million in aggregate One Non - Tradeable Contingent Value Right (CVR) Up to $30.25 per share Appr

  11. Slide 11: Thank You

    Slide 11: Thank You

    Thank You

Source: SEC EDGAR · 8-K filed Nov 13, 2025

More decks from Day One Biopharmaceuticals Inc